Leidos Holdings reports Q2 results on August 4 against a backdrop of persistent analyst pessimism, rising short interest, and a stock that has quietly recovered 12% over the past month — setting up a genuine test of whether the worst is already priced in.
The short-interest picture has shifted noticeably in recent weeks. Bears have added exposure at a steady clip: short interest has climbed nearly 22% over the past month to roughly 4.8% of the free float — a meaningful move, though not yet an extreme reading. The pace accelerated in the final stretch before earnings, with shorts adding around 10% in the past week alone. Cost to borrow has ticked up more than 60% over the same period to 0.56%, signalling rising demand for borrowed shares. That said, the lending market remains far from stressed — availability runs at over 4,000% of short interest, meaning shares are plentiful and there is no mechanical squeeze pressure. The borrowing signal is directionally cautious, not structurally dangerous.
Options positioning adds a modest layer of defensiveness, though nothing dramatic. The put/call ratio edged up to 0.49 on Friday — about one standard deviation above its 20-day average of 0.45. That is a mild tilt toward protection relative to recent norms, well short of the elevated readings seen in late June when the ratio ran above 0.70. On price, the stock closed at $115.60, up 3% on the week and 12% on the month, though still sharply below where it began the year.
The analyst community has spent the past six weeks cutting targets almost uniformly, yet the ratings have largely held. Goldman Sachs lowered its target from $171 to $152 in mid-July while keeping a Neutral rating. JP Morgan trimmed from $210 to $160, maintaining Overweight. Truist and Citigroup made similar downward adjustments without changing their positive stances. The consensus mean target sits near $151 — a 30% premium to the current price — but the direction of travel on those targets is unambiguously lower. The bull case rests on Leidos' diversified government customer base, strong backlog, and potential margin recovery under its NorthStar 2030 strategy. Bears point to the unwinding of the high-margin VA medical exam contract, near-term margin compression, and persistent uncertainty around federal budget allocations. The most recent earnings history adds context worth noting: the May 2026 print sent the stock down roughly 9% on the day and nearly 14% over the following week — a reminder that the market has punished guidance disappointments harshly this year.
Peers offered a mixed read heading into the week: BAH gained nearly 4%, while KBR fell more than 5% and PSN dropped sharply. The divergence suggests the government services sector is trading on individual story lines rather than a single macro tide, which puts the weight squarely on Tuesday's numbers and any commentary around contract awards and the federal budget outlook.
The print will therefore test whether Leidos can demonstrate that margin pressure is bottoming — and whether management's tone on the federal spending environment is enough to justify the gap between the current price and a consensus target that has been moving steadily in the wrong direction.
See the live data behind this article on ORTEX.
Open LDOS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
